Vistagen Therapeutics (NASDAQ:VTGN – Get Free Report) and Disc Medicine (NASDAQ:IRON – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.
Profitability
This table compares Vistagen Therapeutics and Disc Medicine’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Vistagen Therapeutics | -3,421.85% | -35.12% | -32.35% |
| Disc Medicine | N/A | -23.78% | -22.62% |
Institutional and Insider Ownership
78.4% of Vistagen Therapeutics shares are owned by institutional investors. Comparatively, 83.7% of Disc Medicine shares are owned by institutional investors. 1.0% of Vistagen Therapeutics shares are owned by company insiders. Comparatively, 4.2% of Disc Medicine shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Vistagen Therapeutics | $971,000.00 | 84.05 | -$29.36 million | ($2.07) | -1.46 |
| Disc Medicine | N/A | N/A | -$76.43 million | ($3.38) | -14.04 |
Vistagen Therapeutics has higher revenue and earnings than Disc Medicine. Disc Medicine is trading at a lower price-to-earnings ratio than Vistagen Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent ratings and price targets for Vistagen Therapeutics and Disc Medicine, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Vistagen Therapeutics | 0 | 0 | 2 | 1 | 3.33 |
| Disc Medicine | 0 | 1 | 7 | 0 | 2.88 |
Vistagen Therapeutics presently has a consensus target price of $13.50, indicating a potential upside of 347.02%. Disc Medicine has a consensus target price of $64.13, indicating a potential upside of 35.09%. Given Vistagen Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Vistagen Therapeutics is more favorable than Disc Medicine.
Risk and Volatility
Vistagen Therapeutics has a beta of 0.78, suggesting that its share price is 22% less volatile than the S&P 500. Comparatively, Disc Medicine has a beta of 0.59, suggesting that its share price is 41% less volatile than the S&P 500.
Summary
Vistagen Therapeutics beats Disc Medicine on 8 of the 14 factors compared between the two stocks.
About Vistagen Therapeutics
Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.
About Disc Medicine
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.
Receive News & Ratings for Vistagen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vistagen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
